Soligenix announces reverse stock split

Common stock will begin trading on split-adjusted basis on june 6, 2024 princeton, n.j., may 31, 2024 /prnewswire/ -- soligenix, inc. (nasdaq: sngx) (soligenix or the company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is an unmet medical need, announced today that it intends to effect a reverse stock split of its common stock at a ratio of 1 post-split share for every 16 pre-split shares.
SNGX Ratings Summary
SNGX Quant Ranking